GPR162 and Alzheimer disease: In discover cohort, as expected, GABRD+ carrying pTau217 EVs (p < 0.0001), GABRD+ EVs (p < 0.0001) and GPR162+ carrying pTau217 EVs (p < 0.05) were significantly associated with the diagnosis of AD vs HC.